Attached To Lymphokine, Cytokine, Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator Specific For A Hematopoietic Cell (e.g., Interferon, Interleukin, Macrophage Factor, Colony Stimulating Factor, Erythropoietin); Derivative Thereof Patents (Class 424/1.41)
  • Patent number: 10961310
    Abstract: Methods and compounds for conferring site-specific or local immune privilege.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: March 30, 2021
    Assignee: PANDION OPERATIONS, INC.
    Inventors: Joanne L. Viney, Nathan Higginson-Scott, Micah Benson, Alan Crane
  • Patent number: 10828315
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: November 10, 2020
    Assignee: MADRIGAL PHARMACEUTICALS, INC.
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying, Junyi Zhang, Teresa Kowalczyk-Przewloka, Jun Jiang, Sami Osman, Genliang Lu, Dharma Vutukuri, James Loch, Shoujun Chen
  • Patent number: 10434198
    Abstract: The present invention relates to radiopharmaceutical compositions comprising the mother nuclide 224Ra, its daughter nuclide 212Pb, and a complexing agent that complexes with the daughter nuclide. The use of targeted chelate scavengers for 224Ra daughter nuclide opens up the possibility for using 224Ra based solutions for medial treatments.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: October 8, 2019
    Assignee: Sciencons AS
    Inventor: Roy Hartvig Larsen
  • Patent number: 9950019
    Abstract: Disclosed herein are compounds, extracts, and active fractions of the plant Geum japonicum and methods for preventing or treating brain diseases or conditions, such as ischemic stroke, Alzheimer's disease, vascular dementia, mild cognitive impairment (MCI), chronic cerebral ischemia and Parkinson's disease. The compounds provided herein can be formulated into pharmaceutical compositions and medicaments that are useful in the disclosed methods. Also provided are the use of the compounds and extracts in preparing pharmaceutical formulations and medicaments.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: April 24, 2018
    Assignee: GENEREX PHARMACEUTICALS, INC.
    Inventors: Ming Li, Zhen Zhou
  • Patent number: 9855300
    Abstract: The invention relates to a composition and method used for injuries treatment with a surprisingly therapeutic effect. This composition comprises a population of cells derived from human umbilical cord blood which expresses one of the following markers: CD34, CD45, and CD31; a population of CD34+ derived endothelial cells; and a biomimetic gel, preferably fibrin. The method for obtaining the composition comprises the derivation of a population of endothelial cells from CD34+ cells and then a co-culture of a CD34+ cells with CD34+-derived endothelial cells within a biomimetic gel.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: January 2, 2018
    Assignee: CRIOESTAMINAL, SAÚDE E TECNOLOGIA, SA.
    Inventors: Lino Da Silva Ferreira, Dora Cristina Dos Santos Pedroso
  • Patent number: 9771625
    Abstract: A mechanism of monoamine oxidases (MAOs) driven epithelium-to-mesenchymal transition (EMT) is disclosed. Also disclosed are methods for treating cancer by inhibiting or suppressing MAOs in cancer cells. Novel MAOs inhibitors, such as small molecules, siRNA, shRNA, antisense oligonucleotides, aptamers, decoys, and pharmaceutical compositions useful for treating cancer by disrupting the workings of MAOs are provided. In particular, a class of conjugates formed by covalently conjugating near infrared dye 783, IR-780, and MHI-148 to a MAO inhibitor, such as clorgyline, with and without encapsulation it in a nanoparticle is provided. Other aspects of the invention include methods for forming the nano-conjugates, method for monitoring treatment progress in a cancer patient by monitoring the changes in MAO activity, methods for screening patients who are at risk of cancer or differentiating different forms of cancer by assaying the level and location of MAO activity.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: September 26, 2017
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Jean C. Shih, Leland Chung, Haiyen E. Zhau, Boyang Jason Wu, Bogdan Z. Olenyuk
  • Patent number: 9498542
    Abstract: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-?2b.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: November 22, 2016
    Assignee: Immunomedics, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
  • Patent number: 9403906
    Abstract: The present invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in inducing cell death and/or inhibiting the growth and/or proliferation of cells associated with a solid tumour, wherein the cells express IL1RAP. A related aspect of the invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in detecting pathological cells associated with a solid tumor, wherein the cells express IL1RAP. Further provided are pharmacological compositions comprising the agents of the invention and methods of using the same.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: August 2, 2016
    Assignee: Cantargia AB
    Inventors: Thoas Fioretos, Marcus Jaras
  • Patent number: 9365617
    Abstract: Provided are activated collagen scaffold materials as well as their special fused active restoration factors useful for promoting tissue repair, such as bone damage repair or nerve injury repair. The special fused active restoration factors are fusion proteins comprising a collagen-binding domain (CBD) at N-/C-terminus of cytokines, wherein the collagen-binding domain is a polypeptide consisting of 7-27 amino acid residues with a conservative sequence shown in SEQ ID NO:4 at N-terminus.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: June 14, 2016
    Assignee: YANTAI ZHENGHAI BIO-TECH CO., LTD
    Inventors: Jianwu Dai, Bing Chen, Hang Lin, Wenjie Sun, Wenxue Zhao
  • Patent number: 9360414
    Abstract: A method to measure the volume of fluid present that relies on the pattern of light refraction as it passes though an airway surface liquid (ASL) meniscus. The method comprises allowing epithelial cells to grow on a membrane in a well so as to form a fluid meniscus about the perimeter of the well. The well is then illuminated by a light source. The illuminated cells in the well are then optically imaged by a scanner, a flat bed optical scanner, a camera, or any device capable of imaging. Microscopy may be used but is not needed, and high powered microscopy is certainly not needed. Then the imaging information from the cells in the well is used to determine a property of the meniscus in the well. Specifically, the imaging information can be analyzed to determine the dimensions, shape, and/or volume of the meniscus and the fluid in the well.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: June 7, 2016
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventor: Michael Myerburg
  • Patent number: 9012372
    Abstract: The invention relates to the field of biomedical and pharmacological research, in particular to the area of immunology, allergies and autoimmune diseases. The inventors have shown that SWAP-70 is a higher-level regulator for STAT-6 and BCL-6, the regulator being specific for IgE production in B-cells by amplifying the effect of STAT-6 and antagonizing the effect of BCL-6. The inventors have observed no influence of SWAP-70 on the expression of other genes that are likewise regulated by STAT-6 and/or BCL-6. In summary, it can be concluded that SWAP-70 positively regulates IgE production by shifting the interaction of the two antagonists STAT-6 and BCL-6 with regulatory elements of the IgE gene in favor of the activator STAT-6. Based on said findings, the invention provides a screening method which allows for identifying novel active agents that specifically inhibit IgE production.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: April 21, 2015
    Assignee: Albonia Biotech, Inc.
    Inventors: Rolf Jessberger, Tatsiana Audzevich
  • Patent number: 9005617
    Abstract: An antikine antibody binds to two, three, four, five or more CC chemokines, such as RANTES/CCL5, MIP-1?/CCL3, MIP-1?/CCL4, or MCP-1/CCL2. Methods for affinity maturation and humanization of antikine antibodies as well as the production of hybridoma cell lines producing antikine antibodies by sequential immunization are also disclosed.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: April 14, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Dan Allison, Carol Raport
  • Patent number: 8940307
    Abstract: The present invention also relates to a method of reducing metastases in a subject comprising administering to the subject a composition comprising a multifunctional molecule comprising a first part which is capable of binding to an antigen bearing target and a second part which is capable of binding to a cell.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: January 27, 2015
    Assignee: Opsanitx LLC
    Inventors: Andrew H. Segal, Elihu Young
  • Patent number: 8926943
    Abstract: The present invention provides a method for the generation of 223Ra of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising 227Ac, 227Th and 223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting said 223Ra from said strong base anion exchange resin using a first mineral acid in an alcoholic aqueous solution to give a first eluted 223Ra solution; iv) loading the 223Ra of the first eluted 223Ra solution onto a strong acid cation exchange resin; and v) eluting the 223Ra from said strong acid cation exchange resin using a second mineral acid in aqueous solution to provide a second eluted solution. The invention additionally provides products of corresponding purity and/or products obtained or obtainable by such a method.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: January 6, 2015
    Assignee: Algeta ASA
    Inventors: Jan Roger Karlson, Peer Børretzen
  • Patent number: 8906380
    Abstract: Methods are disclosed which are useful in increasing maturation of dendritic cells from CD14+ mononuclear cells, by contact with a composition comprising a fucose-containing glycoprotein fraction from Ganoderma lucidum. The extract can also be used for increasing production of a cytokine or a chemokine in a dendritic cell or CD19+ B cell. In addition, a fucose-containing glycoprotein fraction from Ganoderma lucidum can be administered to a subject identified as needing increased immunoglobulin, cytokine, or chemokine production.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: December 9, 2014
    Assignee: Academia Sinica
    Inventors: Alice Yu, John Yu, Kuo-I Lin, Wen-Bin Yang, Chi-Huey Wong
  • Patent number: 8802433
    Abstract: Disclosed is a highly effective macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages using an active component derived from natural products. A culture obtained by culturing microorganisms belonging to the genus Aureobasidium (Aureobasidium sp.) is used as the active component of the macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages. By means of the macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages, macrophage phagocytosis can be activated, and cytokine production in macrophages can be promoted. In particular, a macrophage phagocytosis-activating composition can activate the phagocytosis of cancer cells or cells damaged or destroyed by anticancer drugs.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: August 12, 2014
    Assignee: Aureo Co., Ltd.
    Inventors: Naoyuki Moriya, Yukiko Moriya, Yasuhiro Nikawa, Yukitoshi Nagahara, Hidekazu Tamegai, Tadaaki Miyazaki
  • Patent number: 8802396
    Abstract: Provided are activated collagen scaffold materials as well as their special fused active restoration factors useful for promoting tissue repair, such as bone damage repair or nerve injury repair. The special fused active restoration factors are fusion proteins comprising a collagen-binding domain (CBD) at N-/C-terminus of cytokines, wherein the collagen-binding domain is a polypeptide consisting of 7-27 amino acid residues with a conservative sequence shown in SEQ ID NO:1 at N-terminus.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: August 12, 2014
    Assignees: Yantai Zhenghai Bio-Technology Co., Ltd., Institute of Genetics and Developmental Biology Chinese Academy of Science
    Inventors: Jianwu Dai, Bing Chen, Hang Lin, Wenjie Sun, Wenxue Zhao
  • Patent number: 8784778
    Abstract: The present invention relates to a method for the in vivo, ex vivo, or in vitro determination of physical or chemical parameters of diagnostic interest by use of a slow tumbling paramagnetic agent that is responsive to changes of said physical or chemical parameter through changes in the R2p/R1p ratio allowing the determination of the said parameter in a manner that is independent on the actual agent concentration.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: July 22, 2014
    Assignee: Bracco Imaging S.p.A.
    Inventors: Silvio Aime, Enzo Terreno
  • Patent number: 8741260
    Abstract: The invention provides compositions, methods, and kits for increasing transport of GDNF across the blood brain barrier while allowing its activity to remain substantially intact. The GDNF is transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: June 3, 2014
    Assignee: Armagen Technologies, Inc.
    Inventors: William M. Pardridge, Ruben J. Boado
  • Publication number: 20140140923
    Abstract: Tin-117m somatoostatin analogues or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic. Also, if desired, it can be administered at a dose that is necrotic and/or induces necrosis, but only to cells within 290 microns of the tin-117m atom. A novel somatostatin analogue is also disclosed, as well as novel methods to produce the tin labeled analogues and antagonists.
    Type: Application
    Filed: November 18, 2013
    Publication date: May 22, 2014
    Applicant: Serene Oncology, LLC
    Inventors: Nigel R. Stevenson, Jaime Simon, Gilbert R. Gonzales
  • Patent number: 8664194
    Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: March 4, 2014
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Antonin de Fougerolles, Kristy M. Wood, Sayda M. Elbashir, Jason P. Schrum
  • Patent number: 8648175
    Abstract: The present invention provides a new stable pharmaceutical composition of erythropoietin (EPO) that is stabilized with PVP.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: February 11, 2014
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Andreja Vukmirovic, Tanja Rozman Peterka, Jelka Svetek, Alenka Paris
  • Publication number: 20130259801
    Abstract: A method for purifying serum amyloid P protein from fresh unfrozen plasma, includes recalcifying the fresh unfrozen plasma and separation by phenyl-type hydrophobic interaction chromatography. The serum amyloid P protein is also obtainable by the method and the use thereof for therapeutic treatment purposes. A method for determining amyloid deposits in a tissue or organ of a subject is also provided.
    Type: Application
    Filed: December 16, 2011
    Publication date: October 3, 2013
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Catherine Chenou, Jean-François Prost
  • Patent number: 8475765
    Abstract: The present invention relates to a method of producing a hydroxyalkyl starch derivative comprising reacting hydroxyalkyl starch of formula (I) at its reducing end which is not oxidized prior to said reaction, with a compound of formula (II) R?NH—R? (II) wherein R1-R2 and R3 are independently hydrogen or a linear or branched hydroxyalkyl group, and wherein either R? or R? or R? and R? comprise at least one functional group X capable of being reacted with at least one other compound prior to or after the reaction of (I) and (II), as well as to the hydroxyalkyl starch derivative as such, obtainable by said method, and to a pharmaceutical composition comprising said hydroxyalkyl starch derivative.
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: July 2, 2013
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Norbert Zander, Harald Conradt, Wolfram Eichner
  • Patent number: 8435488
    Abstract: A modular platform is provided for rapid preparation of various water-soluble prosthetic groups capable to efficiently introduce 18F into proteins with 18F labelling reagents.
    Type: Grant
    Filed: February 25, 2010
    Date of Patent: May 7, 2013
    Assignee: Genentech, Inc.
    Inventors: Herman Gill, Jan Marik, Jeff Tinianow, Simon Williams
  • Patent number: 8372399
    Abstract: A composition having a bispecific antibody which binds a stem cell specific antigen and a tissue, differentiated cell or condition associated antigen and an agent that enhances expression of the tissue, differentiated cell or condition associated antigen, is provided. Also provided are methods of using the bispecific antibodies and/or agents to enhance cell therapy.
    Type: Grant
    Filed: August 31, 2006
    Date of Patent: February 12, 2013
    Assignee: Cardiac Pacemakers, Inc.
    Inventor: Craig Stolen
  • Publication number: 20120294798
    Abstract: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
    Type: Application
    Filed: June 28, 2012
    Publication date: November 22, 2012
    Inventors: Andrew J. Nelson, Steven D. Hughes, Richard D. Holly
  • Patent number: 8313747
    Abstract: An antikine antibody binds to two, three, four, five or more CC chemokines, such as RANTES/CCL5, MIP-1?/CCL3, MIP-1?/CCL4, or MCP-1/CCL2. Methods for affinity maturation and humanization of antikine antibodies as well as the production of hybridoma cell lines producing antikine antibodies by sequential immunization are also disclosed.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: November 20, 2012
    Assignee: VLST Corporation
    Inventors: Dan Allison, Carol Raport
  • Patent number: 8034352
    Abstract: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-?2b.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: October 11, 2011
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
  • Patent number: 8034351
    Abstract: The present invention provides compositions and methods for augmenting vaccine immunogenicity using mucin-immunoglobulin fusion proteins.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: October 11, 2011
    Assignee: Recopharma AB
    Inventor: Jan Holgersson
  • Patent number: 7981398
    Abstract: The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a target agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two target agents and one PEG moiety. In alternative embodiments, the target agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one target agent. In more preferred embodiments, the target agent may comprise any peptide or protein of physiologic or therapeutic activity. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: July 19, 2011
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
  • Publication number: 20110117012
    Abstract: The Invention relates to conjugates of formula (III) or (IIIa), or a salt thereof, their use as radiopharmaceuticals, processes for their preparation, and synthetic intermediates used in such processes.
    Type: Application
    Filed: January 21, 2011
    Publication date: May 19, 2011
    Applicant: GE HEALTHCARE LIMITED
    Inventors: VLADIMIR TOLMACHEV, BENGT LANGSTROM, ASA LILJEGREN SUNDBERG, IRINA VELIKYAN
  • Publication number: 20110085969
    Abstract: Disclosed are methods of imaging a site in a heart of a subject to detect cardiovascular disease that involve stressing a subject, administering to the stressed subject an effective amount of a radionuclide-labeled chelator-glucose analog conjugate, and imaging the heart of the subject by detecting a signal generated by the conjugate in the heart of the subject. Also disclosed are methods of imaging a peripheral blood vessel in a subject by using a detectable amount of a radionuclide-labeled chelator-glucose analog conjugate. Also disclosed are methods of distinguishing a false positive nuclear cardiology scan from a true positive nuclear cardiology scan, methods of diagnosing congestive heart failure or cardiac ischemia that involve imaging a subject that has been administered a radionuclide-labeled chelator-glucose analog conjugate, and methods to distinguish viable from nonviable myocardium.
    Type: Application
    Filed: October 7, 2010
    Publication date: April 14, 2011
    Inventors: F. David Rollo, Jerry L. Bryant
  • Patent number: 7914791
    Abstract: A method for stimulating the immune response to a vaccine applied to a mammalian subject includes the step of administering to the subject an effective amount of EtxB or a molecule having substantially equivalent activity, free from whole toxin and not linked to an antigen.
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: March 29, 2011
    Assignee: Trident Pharmaceuticals, Inc.
    Inventors: Timothy Raymond Hirst, Neil Andrew Williams, Andrew Morgan, Andrew Douglas Wilson, Lucy Amber Bird
  • Patent number: 7906121
    Abstract: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: March 15, 2011
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
  • Publication number: 20110008248
    Abstract: This invention is drawn to methods of using peptide-based antagonists of TGF-beta to facilitate the healing of cutaneous wounds that includes burns, lacerations and scrapes. The administration of peptide TGF-beta antagonists to wounds results in reduced scarring, wound contraction and deposition of extracellular matrix components, and increased rates of reepithelialization during wound healing.
    Type: Application
    Filed: April 27, 2010
    Publication date: January 13, 2011
    Inventor: Jung San Huang
  • Patent number: 7858070
    Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or more IgG antibody fragments and which may be monospecific or bispecific. The disclosed methods and compositions provide a facile and general way to obtain stably tethered structures of virtually any functionality and/or binding specificity. The stably tethered structures may be administered to subjects for diagnostic and/or therapeutic use, for example for treatment of cancer or autoimmune disease. The stably tethered structures may bind to and/or be conjugated to a variety of known effectors, such as drugs, enzymes, radionuclides, therapeutic agents and/or diagnostic agents.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: December 28, 2010
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
  • Patent number: 7855175
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: December 21, 2010
    Assignee: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Palani Balu, Genet Zemede
  • Publication number: 20100284906
    Abstract: The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
    Type: Application
    Filed: June 1, 2010
    Publication date: November 11, 2010
    Applicant: IMMUNOMEDICS, INC.
    Inventors: Hans J. Hansen, Shui-on Leung, Zhengxing Qu, David M. Goldenberg
  • Publication number: 20100266492
    Abstract: A compound for delivering a non-cytotoxic therapeutic moiety into nerve cells, the compound having the general formula: B-L-TM where: B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell; TM is a therapeutic moiety which has a non-cytotoxic therapeutic effect when absorbed by a nerve cell; and L is a linker coupling B to TM.
    Type: Application
    Filed: March 29, 2010
    Publication date: October 21, 2010
    Inventors: Robert R. Webb, Constance A. McKee
  • Patent number: 7815893
    Abstract: The present invention relates to a method of producing a hydroxyalkyl starch derivative comprising reacting hydroxyalkyl starch of formula (I) at its reducing end which is not oxidized prior to said reaction, with a compound of formula (II) R?NH—R? (II) wherein R1-R2 and R3 are independently hydrogen or a linear or branched hydroxyalkyl group, and wherein either R? or R? or R? and R? comprise at least one functional group X capable of being reacted with at least one other compound prior to or after the reaction of (I) and (II), as well as to the hydroxyalkyl starch derivative as such, obtainable by said method, and to a pharmaceutical composition comprising said hydroxyalkyl starch derivative.
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: October 19, 2010
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Norbert Zander, Harald S. Conradt, Wolfram Eichner
  • Publication number: 20100221176
    Abstract: A modular platform is provided for rapid preparation of various water-soluble prosthetic groups capable to efficiently introduce 18F into proteins with 18F labelling reagents.
    Type: Application
    Filed: February 25, 2010
    Publication date: September 2, 2010
    Inventors: Herman Gill, Jan Marik, Jeff Tinianow, Simon Williams
  • Publication number: 20100209341
    Abstract: A method for the treatment of a chronic inflammatory condition in a patient which comprises administration to the patient of an agent which blocks or inhibits IL-3 signalling events in the patient.
    Type: Application
    Filed: February 17, 2010
    Publication date: August 19, 2010
    Inventors: Gino Luigi Vairo, John Allan Hamilton, Andrew David Cook
  • Patent number: 7767407
    Abstract: Methods for the detection and measurement of tagged (labeled) biologically active materials in a sample are described. The tagged biologically active materials are detected using an atomic mass or optical spectrometer having a source of atoms or atomic ions. Element-labeled biologically active materials, comprising antibodies, antibody Fab? fragments, antigens, aptamers, protein complexes, growth factors, hormones, receptors and other biologically active materials attached to a stable elemental tag, can be used in specific binding assays and measured by elemental spectroscopic detection. Also described are methods for the determination of metals in samples of interest using specific antibodies to isolate the target metals and elemental spectroscopy for detection and quantitation. Kits are provided comprising reagents to detect and measure labeled biologically active materials or labeled competition analytes.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: August 3, 2010
    Assignee: PerkinElmer Health Sciences, Inc.
    Inventors: Vladimir Baranov, Scott Tanner, Dmitry Bandura, Zoe Quinn
  • Patent number: 7708978
    Abstract: The present invention relates to an active targeted water-solubility macromolecule polymer, conjugate with interferon and pharmaceutical composition comprising the conjugate. The targeted agent includes, for example, glucose, galatose and the like, as well as their derivates. The conjugate of the present invention is well in water-solubility and have long physiological cycle half-life period, and have specific recognition to pathology organize, improved and increased medication effect of interferon to Hepatitis B, Hepatitis C etc. infectivity sickness and cancer, infect complication etc.
    Type: Grant
    Filed: December 27, 2002
    Date of Patent: May 4, 2010
    Assignee: Beijing Jiankai Technology Co., Ltd.
    Inventors: Shishan Ji, Dequan Zhu
  • Patent number: 7700295
    Abstract: Methods for the detection and measurement of tagged (labeled) biologically active materials in a sample are described. The tagged biologically active materials are detected using an atomic mass or optical spectrometer having a source of atoms or atomic ions. Element-labeled biologically active materials, comprising antibodies, antibody Fab? fragments, antigens, aptamers, protein complexes, growth factors, hormones, receptors and other biologically active materials attached to a stable elemental tag, can be used in specific binding assays and measured by elemental spectroscopic detection. Also described are methods for the determination of metals in samples of interest using specific antibodies to isolate the target metals and elemental spectroscopy for detection and quantitation. Kits are provided comprising reagents to detect and measure labeled biologically active materials or labeled competition analytes.
    Type: Grant
    Filed: July 3, 2003
    Date of Patent: April 20, 2010
    Assignee: MDS SCIEX
    Inventors: Vladimir Baranov, Scott Tanner, Dmitry Bandura, Zoe Quinn
  • Patent number: 7682601
    Abstract: The present invention relates to a chelating agent of the general formula: (I), wherein m is 0 or 1; X is NR4 or S; Y is SR5, NHR5 or P(R5)2; R1 and R3 are the same or different and are selected from H, alkyl or aryl; R2 is H, COOH, NHR6 or (CH2)nCOOR6; R4 is H, alkyl, aryl, (CH2)nCOOR6 or (CH2)nOR6; R5 is H, alkyl, aryl, (CH2)nCOOR6 or (CH2)nOR6, R6 is H, alkyl or aryl; n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and when R1?R3?CH3, R2, R4 and R5 are not all three H. The invention further relates to a method and kit for the preparation of radiolabeled biomolecules while using the chelating agent.
    Type: Grant
    Filed: April 15, 2004
    Date of Patent: March 23, 2010
    Assignee: Mallinckrodt Inc.
    Inventors: Isabel Rego Santos, Joao Domingos Galamba Correia, Antonio Manuel Rocha Paulo, Susana Alves, Rute Vitor
  • Patent number: 7629311
    Abstract: A method for delivering a biologic to a human with Alzheimer's-related dementia, comprising administering the biologic parenterally into the perispinal space of the human without direct intrathecal injection, and thereafter positioning the human's head below the horizontal. The method further includes delivering a TNF antagonist to the brain of a human for treating mild cognitive impairment, Alzheimer's related dementia, or vascular dementia, comprising administering the TNF antagonist golimumab parenterally into the perispinal space of the human without direct intrathecal injection, and thereafter positioning the human in a Trendelenburg position, for delivery of the golimumab to the brain via the human's vertebral venous system.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: December 8, 2009
    Inventor: Edward Lewis Tobinick
  • Patent number: 7541018
    Abstract: In one embodiment, a method for treating a cancerous disease is provided which includes characterizing a disease by an overexpression of one or more somatostatin receptors, and exposing the one or more somatostatin receptors to a pharmaceutical composition comprising a somatostatin analogue which binds to the one or more somatostatin receptors.
    Type: Grant
    Filed: March 8, 2007
    Date of Patent: June 2, 2009
    Assignee: University of Bern
    Inventors: Helmut Robert Maecke, Jean Claude Reubi, Hans Rink, Klaus-Peter Eisenwiener
  • Patent number: 7534870
    Abstract: The present invention provides a new stable pharmaceutical composition of erythropoietin (EPO) that is stabilized with a combination of a poloxamer polyol and a polyhydric alcohol.
    Type: Grant
    Filed: July 14, 2003
    Date of Patent: May 19, 2009
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Andreja Vukmirovic, Tanja Rozman Peterka, Jelka Svetek, Alenka Paris